IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

 

Notes

 

01.01.–30.06.2022

 

01.01.–30.06.2021

 

01.04.–30.06.2022

 

01.04.–30.06.2021

Operating income

 

 

 

 

 

 

 

 

 

 

Net gains from securities

 

4

 

 

379 813

 

 

144 258

Foreign exchange gains

 

 

 

780

 

 

60

 

Other income

 

 

 

3

 

4

 

 

1

 

 

 

 

783

 

379 817

 

60

 

144 259

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Net losses from securities

 

4

 

(510 645)

 

 

(222 239)

 

Finance expenses

 

 

 

(591)

 

(397)

 

(343)

 

(354)

Foreign exchange losses

 

 

 

 

(474)

 

 

(681)

Administrative expenses

 

7

 

(19 900)

 

(25 985)

 

(9 415)

 

(12 907)

Other expenses

 

 

 

(2 534)

 

(3 428)

 

(1 108)

 

(1 751)

 

 

 

 

(533 670)

 

(30 284)

 

(233 105)

 

(15 693)

Profit/(loss) before tax

 

8

 

(532 887)

 

349 533

 

(233 045)

 

128 566

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(39)

 

(38)

 

(20)

 

(19)

Profit/(loss) for the period

 

 

 

(532 926)

 

349 495

 

(233 065)

 

128 547

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(532 926)

 

349 495

 

(233 065)

 

128 547

 

 

 

 

 

 

 

 

 

 

 

Income per share in CHF

 

9

 

(9.66)

 

6.31

 

(4.23)

 

2.32

Diluted income per share in CHF

 

9

 

(9.66)

 

6.31

 

(4.23)

 

2.32

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer